Imagine a world where doctors could give their patients a list of every clinical trial they are eligible to join.

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

An experimental oral drug called muvalaplin shows promise in reducing the cholesterol linked to heart disease in a study.

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Management at Eli Lilly has expressed strong confidence in the growing demand for their obesity franchise and a robust pipeline of new products. The company is anticipating significant benefits from ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

On Friday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $746.2 which represents a decrease of $-40.03 or -5.09% from the prior close of $786.23. The stock opened at $775.19 and ...

This is the online version of STAT's email newsletter Health Care Inc, delivered to your inbox every Monday. Sign up here. ...

The new mens range debuted at a VIP fashion show in Palm Beach last week, and will arrive in stores in February for the ...